Hyperion DeFi (HYPD) Q2 2024 earnings summary

Executive summary

• Advanced multiple initiatives, including Gen-2 Optejet technology, three dry eye collaborations, and two FDA-approved products (Mydcombi and clobetasol), with MicroPine nearing pivotal phase III data readout.

• Net loss for Q2 2024 was $11.1 million ($0.21/share), up from $6.2 million ($0.16/share) in Q2 2023, with six-month net loss at $22.0 million.

• Revenue for Q2 2024 was $22,625, primarily from Mydcombi sales; no revenue in Q2 2023.

• Significant operating expenses included $2.9 million for reacquisition of MicroPine license rights and a $0.5 million inventory write-down.

• Substantial doubt exists about ability to continue as a going concern without additional capital or revenue growth.

Financial highlights

• Q2 2024 net loss: $11.1 million ($0.21/share) on 53.1M shares; revenue: $22,625; cash at June 30, 2024: $2.3 million.

• R&D expenses rose 64% year-over-year to $4.6 million, mainly due to deferred clinical supplies and license reacquisition.

• G&A expenses increased 19% to $3.8 million, driven by sales force hiring and a nonrecurring FDA fee.

• Total operating expenses were $11.2 million, up 88% year-over-year, including $2.9 million in MicroPine repatriation costs and $3.8 million in non-cash expenses.

• Gross loss in Q2 2024 was $467,736, mainly due to a $0.5 million inventory write-down.

Outlook and guidance

• Planning for MicroPine phase III efficacy analysis in Q4 2024; positive results could enable NDA submission by late 2025 or early 2026.

• Gen-2 Optejet device production to start in Q4 2024, with regulatory submission for Mydcombi in 2025.

• Targeting commercial launch of clobetasol by end of summer 2024, with sales force pre-qualifying offices.

• Mydcombi adoption expected to reach over 260 offices by end of Q3 2024.

• Ongoing need to raise additional capital through equity or debt to fund operations and avoid curtailing R&D.